Regulation of COX-2-mediated signaling by α3 type IV noncollagenous domain in tumor angiogenesis

Blood

Volumn 110, Issue 4, 2007, Pages 1168-1177

  Boosani, Chandra Shekhar ^a   Mannam, Arjuna P ^b   Cosgrove, Dominic ^a   Silva, Rita ^c   Hodivala Dilke, Kairbaan M ^c   Keshamouni, Venkateshwar G ^d   Sudhakar, Akulapalli ^a,e,f  

^a BOYS TOWN NATIONAL RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; TUMSTATIN; VERY LATE ACTIVATION ANTIGEN 3;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG BINDING; DRUG INHIBITION; ENDOTHELIUM CELL; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TERATOCARCINOMA; TUMOR GROWTH;

EID: 34548036994     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-01-066282     Document Type: Article

References (55)

1. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell. 1996;87:1153-1155.
2. Distler O, Neidhart M, Gay RE, Gay S. The molecular control of angiogenesis. Int Rev Immunol. 2002;21:33-49.
3. Tryggvason K, Hoyhtya M, Pyke C. Type IV collagenases in invasive tumors. Breast Cancer Res Treat. 1993;24:209-218.
4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
5. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
6. Tryggvason K, Hoyhtya M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta. 1987;907:191-217.
7. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
8. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-285.
9. Kim KS, Kim HS, Park JS, Kwon YG, Park YS. Inhibition of B16BL6 tumor progression by coad-ministration of recombinant angiostatin K1-3 and endostatin genes with cationic liposomes. Cancer Gene Ther. 2004;11:441-449.
10. Indraccolo S, Gola E, Rosato A, et al. Differential effects of angiostatin, endostatin and interferon-alpha( 1) gene transfer on in vivo growth of human breast cancer cells. Gene Ther. 2002;9:867-878.
11. Petitclerc E, Boutaud A, Prestayko A, et al., Hudson BG, Brooks PC. New Functions for Non-collagenous Domains of Human Collagen Type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem. 2000;275:8051-8061.
12. Zhang X, Hudson BG, Sarras MP, Jr. Hydra cell aggregate development is blocked by selective fragments of fibronectin and type IV collagen. Dev Biol. 1994;164:10-23.
13. Colorado PC, Torre A, Kamphaus G, et al. Antiangiogenic cues from vascular basement membrane collagen. Cancer Res. 2000;60:2520-2526.
14. Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha vbeta 3 and alpha 5beta 1 integrins. Proc Natl Acad Sci U S A. 2003;100:4766-4771.
15. Sudhakar A, Nyberg P, Keshamouni VG, et al. Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. J Clin Invest. 2005;115:2801-2810.
16. Pedchenko V, Zent R, Hudson BG. Alpha(v)beta3 and alpha(v)beta5 integrins bind both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of the alpha3 chain of type IV collagen: implication for the mechanism of endothelia cell adhesion. J Biol Chem. 2004;279:2772-2780.
17. Maeshima Y, Sudhakar A, Lively JC, et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science. 2002;295:140-143.
18. Panka DJ, Mier JW. Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells. J Biol Chem. 2003;278:37632-37636.
19. Roth JM, Akalu A, Zelmanovich A, et al. Recombinant alpha2(IV)NC1 domain inhibits tumor cell-extracellular matrix interactions, induces cellular senescence, and inhibits tumor growth in vivo. Am J Pathol. 2005;166:901-911.
20. Magnon C, Galaup A, Mullan B, et al. Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with alphavbeta3 and alphavbeta5 integrins. Cancer Res. 2005;65:4353-4361.
21. Borza CM, Pozzi A, Borza DB, et al. Integrin alpha 3beta 1: a novel receptor for alpha 3 (IV) noncollagenous domain and a trans-dominant inhibitor for integrin alpha vbeta 3. J Biol Chem. 2006;281:20932-20939.
22. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673-687.
23. Miyoshi T, Hirohata S, Ogawa H, et al. Tumor-specific expression of the RGD-alpha3(IV)NC1 domain suppresses endothelial tube formation and tumor growth in mice. Faseb J. 2006;20:1904-1906.
24. Boosani CS, Sudhakar A. Cloning, purification, and characterization of a non-collagenous antiangiogenic protein domain from human alpha1 type IV collagen expressed in Sf9 cells. Protein Expr Purif. 2006;49:211-218.
25. DiPersio CM, Hodivala-Dilke KM, Jaenisch R, Kreidberg JA, Hynes RO. alpha3beta1 Integrin is required for normal development of the epidermal basement membrane. J Cell Biol. 1997;137:729-742.
26. Hodivala-Dilke KM, DiPersio CM, Kreidberg JA, Hynes RO. Novel roles for alpha3beta1 integrin as a regulator of cytoskeletal assembly and as a trans-dominant inhibitor of integrin receptor function in mouse keratinocytes. J Cell Biol. 1998;142:1357-1369.
27. Kreidberg JA, Donovan MJ, Goldstein SL, et al. Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Development. 1996;122:3537-3547.
28. Conti FJ, Rudling RJ, Robson A, Hodivala-Dilke KM. alpha3beta1-integrin regulates hair follicle but not interfollicular morphogenesis in adult epidermis. J Cell Sci. 2003;116:2737-2747.
29. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705-716.
30. Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med. 1999;5:1418-1423.
31. Church RD, Fleshman JW, McLeod HL. Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. Br J Surg. 2003;90:1055-1067.
32. Reynolds LE, Wyder L, Lively JC, et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med. 2002;8:27-34.
33. Mariyama M, Leinonen A, Mochizuki T, Tryggvason K, Reeders ST. Complete primary structure of the human alpha 3(IV) collagen chain. Coexpression of the alpha 3(IV) and alpha 4(IV) collagen chains in human tissues. J Biol Chem. 1994;269:23013-23017.
34. Sudhakar A, Krishnamoorthy T, Jain A, et al. Serine 48 in initiation factor 2 alpha (eIF2 alpha) is required for high-affinity interaction between eIF2 alpha(P) and eIF2B. Biochemistry. 1999;38:15398-15405.
35. Sudhakar A, Ramachandran A, Ghosh S, Hasnain SE, Kaufman RJ, Ramaiah KV. Phosphorylation of serine 51 in initiation factor 2 alpha (eIF2 alpha) promotes complex formation between eIF2 alpha(P) and eIF2B and causes inhibition in the guanine nucleotide exchange activity of eIF2B. Biochemistry. 2000;39:12929-12938.
36. Senger DR, Claffey KP, Benes JE, Perruzzi CA, Sergiou AP, Detmar M. Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proc Natl Acad Sci U S A. 1997;94:13612-13617.
37. Tsukaguchi H, Sudhakar A, Le TC, et al. NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele. J Clin Invest. 2002;110:1659-1666.
38. Wu G, Mannam AP, Wu J, et al. Hypoxia induces myocyte-dependent COX-2 regulation in endothelial cells: role of VEGF. Am J Physiol Heart Circ Physiol. 2003;285:H2420-H2429.
39. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A. 1995;92:4562-4566.
40. Juarez JC, Guan X, Shipulina NV, et al. Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain. Cancer Res. 2002;62:5344-5350.
41. Martin GR. Teratocarcinomas as a model system for the study of embryogenesis and neoplasia. Cell. 1975;5:229-243.
42. Shahan TA, Ziaie Z, Pasco S, et al. Identification of CD47/integrin-associated protein and alpha(v) beta3 as two receptors for the alpha3(IV) chain of type IV collagen on tumor cells. Cancer Res. 1999;59:4584-4590.
43. Maeshima Y, Colorado PC, Kalluri R. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem. 2000;275:23745-23750.
44. Folkman J, Haudenschild C. Angiogenesis by capillary endothelial cells in culture. Trans Ophthalmol Soc UK. 1980;100:346-353.
45. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69:11-25.
46. Maeshima Y, Colorado PC, Torre A, et al. Distinct antitumor properties of a type IV collagen domain derived from basement membrane. J Biol Chem. 2000;275:21340-21348.
47. Kamphaus GD, Colorado PC, Panka DJ, et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem. 2000;275:1209-1215.
48. Zachary I, Rozengurt E. Focal adhesion kinase (p125FAK): a point of convergence in the action of neuropeptides, integrins, and oncogenes. Cell. 1992;71:891-894.
49. Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science. 1995;268:233-239.
50. Kim YM, Hwang S, Pyun BJ, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem. 2002;277:27872-27879.
51. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res. 2002;90:1243-1250.
52. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst. 1998;90:1609-1620.
53. Brambilla R, Neary JT, Cattabeni F, et al. Induction of COX-2 and reactive gliosis by P2Y receptors in rat cortical astrocytes is dependent on ERK1/2 but independent of calcium signalling. J Neurochem. 2002;83:1285-1296.
54. Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res. 2003;37:179-192.
55. Leung WK, To KF, Go MY, et al. Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma. Int J Oncol. 2003;23:1317-1322.